“Promising” Discovery: Identification of Cancer-Causing Immune Cells
A recent study has uncovered the connection between chronic inflammation, the immune system, and cancer development, particularly in the intestines, paving the way for new therapeutic and preventive possibilities, and reducing the risks of this disease.
Researchers identified a mechanism by which certain immune cells, particularly the TH17 lymphocyte subtype, contribute to cancer formation. This discovery raises concerns about the prolonged use of immunotherapies that stimulate these lymphocytes and opens the door to new preventive treatments targeting this subtype to reduce cancer risk, according to “Euronews.”
This is a “promising discovery” made by research teams from Claude Bernard University Lyon 1 and the University of Montpellier in France, according to the same source.
-
A promising technology for early detection of lung cancer
-
The ‘Mad Pandemic’… A Disease More Common Than Heart Disease and Cancer
The joint study found that a category of white blood cells in the intestines may promote cancer development. The researchers, who studied a group of immune cells, the TH17 lymphocytes, present in the intestines, published their findings in Nature Immunology.
Nearly one in three types of cancer develops as a result of chronic inflammation, the origin of which remains poorly understood.
-
Identifying the protein associated with Pancreatic Cancer
-
Four factors behind a “disturbing” rise in new cancer cases
In this new study, researchers identified lymphocytes involved in inflammatory processes, which may contribute to cancer formation. This work “opens new therapeutic and preventive perspectives,” according to the site.
The French science magazine “Futura Sciences” stated that about 30% of cancer cases result from localized chronic inflammation, particularly in cases of colon, rectal, small intestine, liver, and even pancreatic cancers. However, many questions remain unanswered to better understand the development of these cancers.
-
“Calcium Storm”: A Highly Potent Drug against Cancer
-
“Deadly Drug” .. Controversial Cancer-Fighting Narcotic
The study aimed to answer questions such as, “Is there one or more immune cells responsible for the inflammatory process leading to cancer? And if so, which cells?”
Julien Marie, research director at the INSERM Cancer Research Center in Lyon, said that this study showed for the first time that “there are in fact eight subtypes of TH17 lymphocytes with distinct roles, one of which has a tumor-promoting role. That is, when certain activation brakes are lifted, it contributes to cancer development,” he explained.
